The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Mural Oncology a clinical-stage oncology company focused on discovering and developing immunotherapies, held its first ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...